Clinical Trials Incentive Program

Captured cycle: This page is retained for historical guidance. Confirm whether the program has reopened before planning an application.

Clinical Trials Incentive Program

If your team is building a medical technology, biotech therapy, diagnostic method, or digital health intervention and is now moving into human testing, this is the type of opportunity you should evaluate before spending too many cycles on unrelated grant tracks. The recorded program details describe partial cost support from the Israel Innovation Authority (IIA) at 30% to 50% of approved clinical trial costs, aimed at Israeli life sciences teams.

That support is meaningful for real human-testing plans, but the exact page used in this record is currently unavailable and returns 404. The first step is therefore to make sure you are deciding on the right program call, not just reusing a stale template.

This rewrite is written for normal readers and startup teams: what the opportunity is, what is likely within scope, what is probably not, how to judge your readiness, and what to do next.

Why this page needs to be practical

A lot of teams lose time on two mistakes. First, they treat any IIA page with a 30% to 50% number as if funding is guaranteed and can be planned like revenue. Second, they keep applying to links or paths that have moved without checking. If either happens, effort is wasted.

This page avoids that by separating:

• what is currently recorded,
• what is still unverified for current intake,
• and what you can prepare now to be application-ready regardless of where the exact call lands.

Overview

The record positions this as a grant for clinical-stage support, likely most relevant after your technology has enough maturity to define and run a trial in practice. It is not primarily an early ideation subsidy.

Based on the recorded details:

• it targets Israeli companies,
• it focuses on clinical trials for innovative medical technologies and therapeutics,
• and it indicates support between 30% and 50% of approved trial costs.

The listed deadline in the record is 2025-03-24. That is in the past relative to the current date used for this review. This suggests that either this was a past cycle or the call has moved and should be confirmed through current official channels before submission planning.

At-a-glance table

What this program is probably meant to support

A realistic interpretation

This looks like support for teams already at the pre-commercial or commercial proof point who need financial support for trial execution.

For most startup teams, this means:

• you can define a clear trial intervention,
• you can show preliminary evidence and risk logic,
• and your team can execute an organized study rather than a one-off pilot.

In a concrete sense, this is usually where the program can help:

• direct clinical budget items such as protocol setup and execution steps,
• defined monitoring and quality components,
• trial-specific operational spend,
• and patient study execution readiness.

A practical framing of what this is probably not for

• This is unlikely to replace total project financing.
• It is unlikely to be intended for ideas that have no clinical pathway yet.
• It is unlikely to cover broad business-level operating overhead unrelated to approved trial work.

You can think of it as a bridge mechanism in one stage of development, not a full runway engine.

What this means for your funding strategy

A 30% to 50% contribution on an approved trial budget can change your plan significantly, but only if your budget is built in a way that exposes that reduction clearly.

Suppose you plan an approved clinical spending block of ILS 4,000,000. At the recorded rates, the support range would be approximately:

• ILS 1,200,000 at 30%,
• ILS 2,000,000 at 50%.

That reduces your gap, but the remaining 50% to 70% still needs to be covered through your own resources, partners, or other financing lines.

If your total execution needs depend heavily on one-time equipment purchase, long recruitment duration, or expensive external monitoring, test the math early. Do not submit only a “gross support request.” Submit a budget architecture that shows what is covered and what remains.

Current status check and implications

What was verified

• The direct English URL recorded in the existing metadata returns 404 at the check time.
• The official English programs index did not surface this exact dedicated page in the accessible listing.
• No clear direct replacement English page was confirmed from the verified search path used here.

What this implies for you

• Do not treat this as an active open call by default.
• Use this as a readiness document.
• Confirm whether the opportunity has been archived, renamed, merged, or replaced before finalizing submission materials.
• If you are already in active submission mode for IIA support, shift to whichever current IIA call matches your stage.

Who this is for

Your opportunity fit should pass a few filters before you spend more than a weekend preparing a grant package.

Good fit when you can answer yes to most of these

• You are an Israeli legal entity that can be the formal applicant.
• You have a concrete clinical question tied to a defined intervention.
• You already have a coherent trial logic and expected patient pathway.
• You can explain the direct trial spend category by category.
• You can identify realistic roles: clinical lead, operations lead, finance owner, and data/compliance owner.

Also positive signs

• Your team has or is building formal external clinical support (site, investigator, CRO, hospital relationship).
• You can discuss recruitment assumptions without hand-waving.
• You have contingency planning for slow recruitment, delays, and documentation bottlenecks.

Who this is probably not for yet

• Early idea-stage projects without enough pre-trial evidence.
• Teams with unbounded “marketing” style value propositions but no trial mechanics.
• Teams that cannot separate trial costs from general company spend.
• Teams with unresolved governance or governance documents and no assigned accountability.

If your program seems promising but not ready, this is usually a one-cycle delay. Use that delay to increase execution readiness.

Eligibility criteria interpretation from the recorded text

The recorded opportunity text names three broad conditions. Treat these as a required baseline, not an exhaustive checklist:

• Israeli companies conducting clinical trials.
• Focus on innovative medical technologies and therapeutics.
• Clinical activity conducted in Israel or approved locations.

Interpreting each in plain terms

1) Israeli legal and operational readiness

This should show that your company is not just conceptually Israeli, but operationally actionable. Typical evidence includes company registration, formal applicant authority, and clear financial execution structure.

2) Innovative medical project relevance

Show what specific clinical problem is being tested, why that intervention is needed, and what is different or improved versus existing options. This avoids generic claims and keeps your submission focused.

3) Real clinical activity model

If you plan in Israel, state where and how. If the study has approved external segments, state those clearly and explain why they are needed.

In both cases, reviewers look for coherence between technology claims and feasibility.

Application readiness framework (use this first)

Use this as your pre-submission process, regardless of whether this exact listing stays active.

Phase 1: Confirm status and channel (days 1 to 3)

1. Verify current official status and submission status.
2. Save your status evidence with date and URL.
3. Confirm whether this exact call is available or has been replaced.

You should spend time on this first, before polishing narrative text.

Phase 2: Clinical thesis and endpoint definition (days 4 to 10)

1. Write a one-page narrative that answers:
   • what is the medical problem,
   • what intervention is being tested,
   • what endpoint matters,
   • what changes after success.
2. Document why this intervention is trial-ready now.
3. Keep all assumptions explicit and testable.

Phase 3: Trial operations package (week 2)

1. Draft a protocol summary and high-level study schedule.
2. Define population, inclusion logic, expected flow, and stop/go criteria.
3. Create a risk register that includes recruitment delays and protocol amendment triggers.

Phase 4: Financial architecture (week 3)

1. Build a dedicated trial budget, with line items only for eligible-type activity.
2. Add a second column for your matching contribution.
3. Add a third column for contingency reserves.
4. Tie each budget line to a trial deliverable and timeline.

Phase 5: Evidence and partner readiness (week 3-4)

1. Gather letters or commitment statements that specify partner roles.
2. Add prior evidence that is directly connected to trial readiness.
3. Create one-page role charts showing who is accountable for each function.

Phase 6: Internal review and hardening (week 4)

1. Have your team score clarity, realism, and budget quality.
2. Remove claims that are generic.
3. Reduce the package to essentials a reviewer can verify quickly.

Phase 7: Decision gate

If official submission status is confirmed active, move to submission prep. If not confirmed, pause before final submission and keep your pack warm for the next active pathway.

Required materials checklist

What to include in your timeline planning

A realistic timeline for readiness is more important than a perfect submission date:

• week 1: status verification and scope decision,
• week 2: trial and operational design draft,
• week 3: budget and evidence pack,
• week 4: internal review and final adjustments.

Because the listed date is historical, do not backfill to this old deadline without official revalidation.

Practical clues that separate a strong pack from a weak one

Strong pack clues

• Your trial objective is plain in one paragraph.
• Every budget line is tied to a trial deliverable.
• Risks are described with specific ownership.
• Partners are named with roles, not just logos.

Weak pack clues

• Generic claims with no execution detail.
• A budget that mixes company overhead and trial execution.
• Vague or symbolic letters with unclear commitments.
• “We can handle any recruitment challenge” without numbers.

Common mistakes and how to avoid them

Mistake 1: Assuming the URL means the call is active

Avoid this by setting a hard rule: no final version without status confirmation in the same review cycle.

Mistake 2: Using unsupported language in the protocol

Do not use broad “we expect good results” statements. Use measurable assumptions and fallback actions.

Mistake 3: Submitting a funding-first argument

Make the trial-first argument first. The funding contribution should be framed as the practical consequence of a strong trial plan.

Mistake 4: Leaving ownership unclear

At least four ownership lanes should be explicit: clinical, operations, finance, and compliance.

Mistake 5: Under-defining recruitment

If your recruitment estimate is not realistic, reviewers will see fragility. Add sources or assumptions and alternate pathways.

Mistake 6: Hiding delays as future uncertainty

Delay scenarios are not signs of weakness if they are explicit and planned.

FAQ

Q1: Is this opportunity currently open?

No active confirmation appears in the current check record. The legacy URL is not reachable and the dedicated page does not currently appear in the official English list that was reviewed. Confirm through official channels before spending on submission.

Q2: Is the support guaranteed?

No guarantee can be stated from verified records. The recorded range is 30% to 50% of approved trial costs.

Q3: Is a full company trial budget covered?

No. The recorded support is a partial grant percentage and therefore requires matching funding.

Q4: Who is the best applicant profile?

Israeli teams with clear clinical-path execution, documented trial ownership, and a realistic budget and timeline.

Q5: Is this suitable for preclinical teams?

Usually better for teams with a clinical-ready next step. If your product is earlier stage, prepare first and re-enter when your trial design is stronger.

Q6: Can early-stage startups apply?

A small startup can still be suitable, but role coverage and execution design must be real.

Q7: What should be improved before applying?

Prioritize status verification, governance ownership, budget traceability, and recruitment assumptions.

Q8: Should I apply if the call might be closed?

No. Use the package as a readiness sprint, not a final submission sprint.

Q9: What if I get a rejection?

Treat rejection as process feedback if available. Even without approval, the same materials usually transfer to the next active call.

Q10: Can I use this page for another IIA pathway?

Yes. The structure is reusable for many clinical and life science grant submissions because reviewer-readiness patterns are often similar.

Official next steps

1. Verify status on the official IIA channels.
2. Save a timestamped record of that verification.
3. Confirm active program path and submission process.
4. Update your package with only verified requirements.
5. If inactive, reposition for the currently active IIA clinical/life science pathway.

Official links

• Israel Innovation Authority - programs (English)
• Israel Innovation Authority - site map (English)
• Israel Innovation Authority - contact us (English)
• FindMyMoney opportunity record

Final practical checklist before moving forward

Before you submit anything to an active IIA call, ensure you can answer:

• What trial are we running and why is this the right study now?
• What exactly is included in the approved trial budget?
• How will recruitment be measured and corrected if assumptions do not hold?
• Who owns protocol integrity, finance approvals, and compliance?
• What documentation is needed on day one after award?
• Which risks will delay recruitment and what is your alternative pathway?

If these answers are not stable, do not submit yet. Use the next two to four weeks to strengthen readiness and then move.